| Literature DB >> 30340646 |
Senait Tadesse1, Tsega Kahsay2, Gebre Adhanom2, Getachew Kahsu2, Haftom Legese2, Aderajew G/Wahid2, Awoke Derbie3,4.
Abstract
OBJECTIVE: Approach to asymptomatic bacteriuria among pregnant women in Ethiopia is mainly based on clinical grounds and urine strip and microscopy tests. On top of this, the treatment is also on an empirical basis which may leads to an increased antimicrobial resistance. The aim of this study was to assess the prevalence, antimicrobial susceptibility profile and associated factors of asymptomatic bacteriuria among pregnant women attending antenatal clinic in Adigrat Hospital, Northern Ethiopia.Entities:
Keywords: Adigrat General Hospital; Antimicrobial susceptibility profile; Asymptomatic bacteriuria; Pregnant women
Mesh:
Year: 2018 PMID: 30340646 PMCID: PMC6194591 DOI: 10.1186/s13104-018-3844-1
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Bivariate and multivariate analysis of factors associated with asymptomatic bacteriuria among pregnant women attending at Adigrat general hospital, Northern Ethiopia, 2018
| Variables | Categories | ASB | COR (95% CI) | AOR (95% CI) | ||
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Age | 18–25 | 40 | 87 | 3.6 (1.3, 9.7) | 8.5 (2.2, 32.9) | 0.001 |
| 26–33 | 10 | 78 | 1.3 (0.3, 3.2 | 1.6 (0.4, 6.6) | 0.5 | |
| 34–45 | 5 | 39 | 1 | 1 | ||
| Gestational period | 1st trimester | 25 | 40 | 5.8 (2.6, 12.6) | 11.9 (4.4, 32.4) | < 0.001 |
| 2nd trimester | 18 | 53 | 3.1 (1.4, 6.9) | 5.6 (2.0, 15.5) | 0.01 | |
| 3rd trimester | 12 | 111 | 1 | 1 | ||
| Income | > 1000 | 22 | 18 | 7 (2.8, 18.5) | 7.5 (2.4, 23.1) | 0.001 |
| 1000–1999 | 13 | 56 | 1.4 (0.5, 3.4) | 0.96 (0.3, 2.7) | 0.9 | |
| 2000–2999 | 11 | 77 | 0.8 (0.3, 2.2) | 0.6 (0.2, 1.8) | 0.3 | |
| > 2999 | 9 | 53 | 1 | 1 | ||
Antimicrobial susceptibility pattern of bacterial isolates from asymptomatic bacteriuria among pregnant women attending at Adigrat hospital, Nortern Ethiopia, 2018
| Type of isolates | Antimicrobial resistance profile of the isolates, frequency (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| G−ve isolates | Profile | CN | AMC | Amp | CIP | SXT | CRO | F | |
| S | 15 (78.9%) | 16 (84.2%) | 0 (0%) | 14 (73.6%) | 9 (47.4%) | 17 (89.4%) | 14 (73.6%) | ||
| I | 0 (0%) | 1 (5.2%) | 0 (0%) | 1 (5.2%) | 1 (5.2%) | 1 (5.2%) | 0 (0%) | ||
| R | 4 (21.1%) | 2 (10.5%) | 19 (100%) | 4 (21.5%) | 9 (47.4%) | 1 (5.2%) | 5 (26.6%) | ||
| S | 7 (70%) | 8 (80%) | 0 (0%) | 7 (70%) | 6 (60%) | 9 (90%) | 6 (60%) | ||
| I | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| R | 3 (30%) | 1 (10%) | 10 (100%) | 3 (30%) | 3 (30%) | 1 (10%) | 4 (40%) | ||
| S | 4 (80%) | 3 (60%) | 0 (0%) | 4 (80%) | 3 (60%) | 4 (80%) | 4 (80%) | ||
| I | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| R | 1 (20%) | 10 (100%) | 1 (20%) | 2 (40%) | 1 (20%) | 1 (20%) | |||
| S | 2 (66.7%) | 1 (33.3%) | 0 (0%) | 1 (33.3%) | 0 (0%) | 2 (66.7%) | 2 (66.7%) | ||
| I | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| R | 1 (33.3%) | 2 (66.7%) | 3 (100%) | 2 (66.7%) | 3 (100%) | 1 (33.3%) | 1 (33.3%) | ||
| S | 1 (100%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | ||
| I | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| R | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) | ||
| Total (38) | S | 29 (76.3%) | 29 (76.3%) | 0 (0%) | 29 (77.1%) | 18 (47.4%) | 33 (86.8%) | 26 (68.4%) | |
| I | 0 (0%) | 2 (5.2%) | 0 (0%) | 1 (2.6%) | 1 (2.6%) | 1 (2.6%) | 0 (0%) | ||
| R | 9 (23.7%) | 7 (18.4%) | 38 (100%) | 8 (21.1%) | 19 (50%) | 5 (13.2%) | 12 (31.6%) | ||
CN gentamicin, AMC amoxicillin clavulanic acid, AMP ampicillin, CIP ciprofloxacin, SXT trimethoprim/sulfamethoxazole, CRO ceftriaxone, F nitrofurantoin, P penicillin, Ery erythromycin, CL clindamycin, VAN vancomycin, S sensitive, I intermediate, R resistant